Zhengzi Qian

机构：Tianjin Medical University Cancer Institute and Hospital

发表论文 64 篇 · 总被引 680 次 · h-index 13

代表论文

• Adverse events in the nervous system associated with blinatumomab: a real-world study (2025 · BMC Medicine · 被引 24)
• Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial (2025 · The Lancet · 被引 20)
• Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B‐Cell Lymphoma: A Real‐World, Multi‐Center, Retrospective Cohort Study (2024 · Hematological Oncology · 被引 15)
• GB261, an Fc-Function Enabled and CD3 Affinity De-Tuned CD20/CD3 Bispecific Antibody, Demonstrated a Highly Advantageous Safety/Efficacy Balance in an Ongoing First-in-Human Dose-Escalation Study in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (2023 · Blood · 被引 13)
• Phase II study of novel orally PI3Kα/δ inhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma (2024 · Signal Transduction and Targeted Therapy · 被引 11)
• A retrospective analysis of mature T- and NK-cell lymphomas (2024 · Cancer Biology and Medicine · 被引 6)